A Phase 2 interventional study of Placebo and Atacicept 25 mg in IgA Nephropathy, sponsored by EMD Serono Research & Development Institute, Inc.. Terminated at 18 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-25.
Sponsored by EMD Serono Research & Development Institute, Inc. (part of Merck KGaA, Darmstadt, Germany) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies in Glomerulonephritis, IGA with a site in United States — 27 open to participants now, 39 under way, 18 of them phase 3. Glomerulonephritis, IGA · United States.
Among the 75 studies in Glomerulonephritis, IGA with a site in United States, this one is the 60th largest by enrollment of the 69 interventional ones that give a count, is one of 2 that started in 2017, is one of 30 in phase 2, and was the 16th registered.
276 studies on the registry are indexed under Glomerulonephritis, IGA; 107 are open to participants now.
Browse Glomerulonephritis, IGA studies →27 of the 75 studies in Glomerulonephritis, IGA with a site in United States are open now. Recruiting first, the newest first:
Jade Biosciences, Inc. · Sites in United States
Ages 18+
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Australia, Israel
Ages 18+
argenx · Sites in United States, Japan
Ages 18+
Pediatric Nephrology Research Consortium · Sites in United States
Ages up to 18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 33 · Phase 3 24 · Phase 4 7
First in 1997; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 62 across 221 interventional studies indexed under Glomerulonephritis, IGA.
Median enrollment 72 across the 69 interventional studies, 744 across the 6 observational. Of the 34 that completed or were terminated, 25 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 75 have an industry lead sponsor. The 10 most frequent:
This study is registered under EMD Serono Research & Development Institute, Inc., one of the names counted as Merck KGaA, Darmstadt, Germany. Under that name alone:
EMD Serono Research & Development Institute, Inc. is the lead sponsor of 87 studies on the registry; 8 are open to participants now.
Of its 47 completed or terminated interventional studies of FDA-regulated products, 38 (81%) have results posted.
Merck KGaA, Darmstadt, Germany has 1 study filed under Glomerulonephritis, IGA — fewer than ten, so there is no comparison to draw.
8 of the studies in Glomerulonephritis, IGA with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06935357Phase 3BiogenA Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) | 2027-05-31 |
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
| NCT06712407Calliditas Therapeutics ABEfficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy | 2027-03 |
| NCT06466135Walden BiosciencesStudy of WAL0921 in Patients With Glomerular Kidney Diseases | 2027-03 |
| NCT05003986Travere Therapeutics, Inc.Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases | 2027-03-12 |
Add all 8 to your calendar (.ics) → With an account.
Among the 75 studies in Glomerulonephritis, IGA with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This main purpose of this study was to evaluate the safety, tolerability, dose response and efficacy of Atacicept in participants with IgA nephropathy and persistent proteinuria. The study hypothesis was that treatment with Atacicept would reduce proteinuria compared to placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo
Drug: Atacicept 25 mg
Drug: Atacicept 75 mg
Participants received placebo matched to Atacicept once weekly as subcutaneous (SC) injection during this study up to a maximum of 72.1 weeks.
Participants received 25 milligrams (mg) of Atacicept once weekly as SC injection during this study up to a maximum of 73.6 weeks.
Participants received 75 mg of Atacicept once weekly as SC injection during this study up to a maximum of 74.1 weeks.
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs), Adverse Event of Special Interest (AESIs), Serious TEAEs, TEAEs Leading to Discontinuation and TEAEs Leading to Death
Adverse Event (AE): any untoward medical occurrence in a participant administered with a study drug, which does not necessarily had a causal relationship with this treatment. Serious AE: AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAEs: AEs that developed or worsened/became serious during on-treatment period (time from the first dose of study drug up to the end of study \[Week 96\]). TEAEs included serious AEs and non- serous AEs. AESIs included infections, cardiac failure, cardiomyopathy/ ischemic heart disease, hypersensitivity reaction (including anaphylactic/anaphylactoid shock conditions, asthma/bronchospasm, and angioedema), injection site reactions (ISRs) and demyelinating disorders. Investigator or his /her designee assessed ISRs as local reactions (redness, bruising, swelling, induration and itching).
Time frame: Baseline up to 96 weeks
Serum Atacicept Concentrations
Serum Atacicept Concentrations was to be performed; however; as per changed in planned analysis the outcome measure related to pharmacokinetic parameters was not assessed.
Time frame: Week 0 Day 1 (pre-dose), Weeks 1, 2, 4, 8, 12, 16, 24, 40, 48, 72, Early Termination (up to Week 72) and Post-treatment (PT) Follow Up (FU) Weeks 4, 12 and 24
Change From Baseline Levels in Serum Immunoglobulin A (IgA)
The change in serum levels of IgA from baseline was reported.
Time frame: Baseline, Weeks 1, 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, 60, 72, Early Termination (up to Week 72) and PT FU Weeks 4, 12 and 24
Change From Baseline Levels in Serum Iimmunoglobulin G (IgG)
The change in serum levels of IgG from baseline was reported.
Time frame: Baseline, Weeks 1, 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, 60, 72, Early Termination (up to Week 72) and PT FU Weeks 4, 12 and 24
Change From Baseline Levels in Serum Immunoglobulin M (IgM)
The change in serum levels of IgM from baseline was reported.
Time frame: Baseline, Weeks 1, 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, 60, 72, Early Termination (up to Week 72) and at PT FU Weeks 4, 12 and 24
Change From Baseline in Serum Galactose Deficient-IgA1 (Gd-IgA1) Levels
The change in serum Gd-IgA1 from baseline was reported.
Time frame: Baseline, Weeks 4, 12, 24, 48, 72, Early Termination (up to Week 72 and at PT FU Weeks 12 and 24
Change From Baseline in Serum Complement C3 and C4 Levels
The change in serum component C3 and C4 from baseline were reported.
Time frame: Baseline, Week 12, 24, 48, 72, Early Termination (up to Week 72) and at PT FU Weeks 12 and 24
Change From Baseline in Immune Cell Subsets by Flow Cytometry Analysis
Change from baseline in immune cell subsets included total T cells, helper T cells, cytotoxic T cells, total B cells (assay with \[AW\] CD45 or assay without \[AWO\] CD45), mature naïve B cells, memory B cells, plasma cells, plasma blasts, and natural killer (NK) cells and were reported. Analysis was performed by flow cytometry analysis.
Time frame: Baseline, Weeks 4, 12, 24, 48, 72, Early Termination (up to Week 72) and at PT FU Week 24
Change From Baseline in Urinary IgG, IgA, and IgM Levels
Urinary IgG, IgA and IgM levels to be measured by Immuno-Electrophoresis.
Time frame: Baseline (Day1), Weeks 24, 48 and Early Termination (up to earlier than Week 72)
Percentage of Participants With Positive Anti-Drug Antibody (ADA)
Percentage of participants with positive ADA were reported.
Time frame: Baseline up to safety follow-up (96 weeks)
Percentage of Participants With Clinical Significant Abnormalities in Laboratory Assessments
Laboratory investigation included hematology, biochemistry, urinalysis and Urine sediment analysis. Clinical significance was to be decided by the investigator.
Time frame: Baseline up to safety follow-up (96 weeks)
Percentage of Participants With Clinical Significant Abnormalities in Vital Signs
Vital signs included body temperature, systolic and diastolic blood pressure, pulse rate, weight and height. The systolic and diastolic blood pressure and pulse rate was measured after the participants have in a rested at least 3 minutes in seated position. Clinical significance was to be decided by the investigator.
Time frame: Baseline up to safety follow-up (96 weeks)
Percentage of Participants With Clinical Significant Abnormalities in 12-Lead Electrocardiograms (ECGs)
12-lead ECG were recorded after the participants have rested for at least 15 minutes in supine position. Clinically significance was decided by the investigator. The number of participants with clinically significant abnormalities in 12-lead ECG were reported.
Time frame: Baseline up to safety follow-up (96 weeks)
| Milestone | Placebo | Atacicept 25 mg | Atacicept 75 mg |
|---|---|---|---|
| Started | 5 | 6 | 5 |
| Completed | 2 | 5 | 3 |
| Not completed | 3 | 1 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 |
| Withdrew: Premature study termination by sponsor | 2 | 0 | 1 |
| Withdrew: Relocation | 0 | 0 | 1 |
Adverse Event (AE): any untoward medical occurrence in a participant administered with a study drug, which does not necessarily had a causal relationship with this treatment. Serious AE: AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAEs: AEs that developed or worsened/became serious during on-treatment period (time from the first dose of study drug up to the end of study \[Week 96\]). TEAEs included serious AEs and non- serous AEs. AESIs included infections, cardiac failure, cardiomyopathy/ ischemic heart disease, hypersensitivity reaction (including anaphylactic/anaphylactoid shock conditions, asthma/bronchospasm, and angioedema), injection site reactions (ISRs) and demyelinating disorders. Investigator or his /her designee assessed ISRs as local reactions (redness, bruising, swelling, induration and itching).
| percentage of participants | Placebo | Atacicept 25 mg | Atacicept 75 mg |
|---|---|---|---|
| Participants with TEAE | 100 | 100 | 60 |
| Participants with AESI: Cardiac failure | 0 | 0 | 0 |
| Participants with AESI: Ischaemic heart disease | 0 | 0 | 0 |
| Participants with AESI: Cardiac arrhythmia | 0 | 0 | 0 |
| Partcipants with AESI: Hypersensitivity reactions | 20 | 66.67 | 20 |
| Partcipants with AESI: Demyalinating disorders | 0 | 0 | 0 |
| Partcipants with AESI: Injection site reactions | 0 | 83.3 | 60 |
| Partcipants with AESI: Infections | 40 | 83.33 | 20 |
| Participants with serious TEAEs | 20 | 50 | 0 |
| Participants with TEAEs leading to discontinuation | 0 | 16.66 | 0 |
| Participants with TEAEs leading to death | 0 | 0 | 0 |
Serum Atacicept Concentrations was to be performed; however; as per changed in planned analysis the outcome measure related to pharmacokinetic parameters was not assessed.
No measurements were reported for this outcome.
The change in serum levels of IgA from baseline was reported.
| gram per liter | Placebo | Atacicept 25 mg | Atacicept 75 mg |
|---|---|---|---|
| Change at Week 1 | -0.194 ± 0.3012 | -0.203 ± 0.1325 | -0.278 ± 0.1561 |
| Change at Week 2 | -0.114 ± 0.2825 | -0.280 ± 0.1108 | -0.486 ± 0.2289 |
| Change at Week 4 | -0.014 ± 0.3570 | -0.197 ± 0.1952 | -0.828 ± 0.2319 |
| Change at Week 8 | 0.008 ± 0.5340 | -0.572 ± 0.2838 | -1.144 ± 0.4997 |
| Change at Week 12 | -0.030 ± 0.4011 | -0.476 ± 0.3879 | -1.146 ± 0.4226 |
| Change at Week 16 | 0.044 ± 0.4869 | -0.692 ± 0.3608 | -1.296 ± 0.4237 |
| Change at Week 20 | 0.218 ± 0.6157 | -0.616 ± 0.2880 | -1.430 ± 0.4635 |
| Change at Week 24 | 0.212 ± 0.3140 | -0.514 ± 0.4552 | -1.424 ± 0.5226 |
| Change at Week 32 | 0.180 ± 0.4924 | -0.920 ± 0.2950 | -1.468 ± 0.3851 |
| Change at Week 40 | 0.112 ± 0.7745 | -0.963 ± 0.2815 | -1.388 ± 0.3212 |
| Change at Week 48 | 0.526 ± 1.2935 | -0.710 ± 0.3804 | -1.375 ± 0.4680 |
| Change at Week 60 | 0.233 ± 0.3676 | -0.733 ± 0.3057 | -1.283 ± 0.4308 |
| Change at Week 72 | 0.307 ± 0.3650 | -0.957 ± 0.2157 | -1.240 ± 0.4491 |
| Change at Early termination | 0.420 ± 0.0849 | -0.493 ± 0.2173 | -1.835 ± 0.1344 |
| Change at PT FU Week 4 | 0.300 ± 0.4757 | -0.452 ± 0.3529 | -1.223 ± 0.2515 |
| Change at PT FU Week 12 | 0.622 ± 0.7436 | -0.440 ± 0.6335 | -0.668 ± 0.2843 |
| Change at PT FU Week 24 | 0.563 ± 0.6716 | -0.420 ± 0.6503 | -0.370 ± 0.1160 |
The change in serum levels of IgG from baseline was reported.
| gram per liter | Placebo | Atacicept 25 mg | Atacicept 75 mg |
|---|---|---|---|
| Change at Week 1 | -0.630 ± 0.5524 | -0.480 ± 0.4289 | -0.444 ± 0.4372 |
| Change at Week 2 | -0.362 ± 0.7146 | -0.650 ± 0.5764 | -0.898 ± 0.5507 |
| Change at Week 4 | -0.354 ± 0.7073 | -0.415 ± 0.4965 | -1.792 ± 0.8182 |
| Change at Week 8 | -0.562 ± 1.0023 | -1.128 ± 0.3574 | -2.812 ± 1.2085 |
| Change at Week 12 | -0.472 ± 0.9304 | -0.930 ± 0.7748 | -3.126 ± 0.9324 |
| Change at Week 16 | -0.608 ± 1.1858 | -1.480 ± 0.4687 | -3.360 ± 0.8546 |
| Change at Week 20 | 0.016 ± 1.0781 | -1.024 ± 0.3893 | -3.684 ± 0.7597 |
| Change at Week 24 | -0.748 ± 1.0059 | -0.926 ± 0.8289 | -3.776 ± 1.0876 |
| Change at Week 32 | -0.296 ± 1.1195 | -1.055 ± 0.5701 | -3.962 ± 0.8830 |
| Change at Week 40 | 0.218 ± 0.8904 | -1.363 ± 0.4895 | -3.623 ± 0.2993 |
| Change at Week 48 | 0.256 ± 1.5731 | -0.600 ± 0.7654 | -3.745 ± 0.4608 |
| Change at Week 60 | 0.305 ± 1.2881 | -0.743 ± 1.5627 | -3.368 ± 0.5721 |
| Change at Week 72 | -0.203 ± 1.3606 | -0.867 ± 0.7772 | -3.477 ± 0.8618 |
| Change at Early Termination | 0.655 ± 0.5445 | -1.547 ± 0.5353 | -3.995 ± 0.0636 |
| Change at PT FU Week 4 | 0.360 ± 1.7711 | -0.736 ± 0.7900 | -2.553 ± 0.7160 |
| Change at PT FU Week 12 | 0.922 ± 1.2793 | -0.800 ± 1.4692 | -1.300 ± 0.5610 |
| Change at PT FU Week 24 | 0.273 ± 0.9758 | -0.878 ± 1.0395 | 0.020 ± 1.2498 |
The change in serum levels of IgM from baseline was reported.
| gram per liter | Placebo | Atacicept 25 mg | Atacicept 75 mg |
|---|---|---|---|
| Change at Week 1 | -0.082 ± 0.0835 | -0.072 ± 0.0736 | -0.096 ± 0.0924 |
| Change at Week 2 | -0.054 ± 0.1026 | -0.140 ± 0.1906 | -0.102 ± 0.1625 |
| Change at Week 4 | -0.002 ± 0.1190 | -0.197 ± 0.2655 | -0.410 ± 0.1637 |
| Change at Week 8 | 0.006 ± 0.1710 | -0.302 ± 0.3114 | -0.558 ± 0.1859 |
| Change at Week 12 | 0.022 ± 0.0955 | -0.360 ± 0.3169 | -0.638 ± 0.2497 |
| Change at Week 16 | 0.024 ± 0.1412 | -0.408 ± 0.3531 | -0.710 ± 0.2463 |
| Change at Week 20 | 0.082 ± 0.2288 | -0.444 ± 0.3965 | -0.748 ± 0.2500 |
| Change at Week 24 | -0.016 ± 0.1390 | -0.364 ± 0.3377 | -0.774 ± 0.2517 |
| Change at Week 32 | -0.016 ± 0.1566 | -0.510 ± 0.4498 | -0.796 ± 0.2773 |
| Change at Week 40 | 0.036 ± 0.1464 | -0.247 ± 0.1553 | -0.848 ± 0.2668 |
| Change at Week 48 | 0.012 ± 0.1951 | -0.227 ± 0.1250 | -0.848 ± 0.2557 |
| Change at Week 60 | -0.033 ± 0.0907 | -0.297 ± 0.2495 | -0.843 ± 0.2573 |
| Change at Week 72 | -0.027 ± 0.0153 | -0.337 ± 0.2914 | -0.900 ± 0.3081 |
| Change at Early Termination | 0.115 ± 0.0354 | -0.463 ± 0.1626 | -0.670 ± 0.1414 |
| Change at PT FU Week 4 | -0.048 ± 0.1941 | -0.328 ± 0.1906 | -0.667 ± 0.2259 |
| Change at PT FU Week 12 | 0.058 ± 0.2281 | -0.214 ± 0.1739 | -0.465 ± 0.2319 |
| Change at PT FU Week 24 | 0.020 ± 0.1687 | -0.178 ± 0.1504 | -0.340 ± 0.1896 |
The change in serum Gd-IgA1 from baseline was reported.
| nanogram per milliliter (ng/mL) | Placebo | Atacicept 25 mg | Atacicept 75 mg |
|---|---|---|---|
| Change at Week 4 | -1438 ± 598.2 | -620 ± 1580.4 | -2288 ± 730.5 |
| Change at Week 12 | -380 ± 1505.0 | -1672 ± 1459.2 | -2778 ± 1345.8 |
| Change at Week 24 | 160 ± 848.8 | -1912 ± 1835.0 | -3660 ± 1940.9 |
| Change at Week 48 | 1140 ± 4339.5 | -423 ± 795.1 | -2938 ± 1756.9 |
| Change at Week 72 | 580 ± 2594.8 | -1327 ± 1181.4 | -3202 ± 1594.9 |
| Change at Early Termination | 3520 ± 4638.6 | -2383 ± 2551.1 | -2680 ± 1258.7 |
| Change at PT FU Week 12 | 1926 ± 3523.3 | -772 ± 2050.2 | -818 ± 1277.9 |
| Change at PT FU Week 24 | 1673 ± 5072.9 | -1262 ± 2444.1 | -1090 ± 70.7 |
The change in serum component C3 and C4 from baseline were reported.
| milligram per liter | Placebo | Atacicept 25 mg | Atacicept 75 mg |
|---|---|---|---|
| Complement C3: Change at Week 12 | -60.0 ± 88.32 | 80.0 ± 125.10 | 122.0 ± 114.76 |
| Complement C3: Change at Week 24 | -38.0 ± 100.85 | -6.0 ± 220.64 | 70.0 ± 104.24 |
| Complement C3: Change at Week 48 | 82.0 ± 215.57 | 63.3 ± 110.15 | 162.5 ± 219.91 |
| Complement C3: Change at Week 72 | -56.7 ± 127.41 | 43.3 ± 212.21 | 196.7 ± 196.55 |
| Complement C3: Change at Early Termination | -145.0 ± 190.92 | -60.0 ± 284.78 | 180.0 |
| Complement C3: Change at PT FU Week 12 | -12.0 ± 106.16 | -96.0 ± 196.67 | 170.0 ± 390.00 |
| Complement C3: Change at PT FU Week 24 | -85.0 ± 183.76 | -144.0 ± 93.97 | 164.0 ± 205.45 |
| Complement C4: Change at Week 12 | -26.8 ± 25.35 | 13.4 ± 9.24 | 33.8 ± 44.81 |
| Complement C4: Change at Week 24 | -27.0 ± 32.26 | 8.8 ± 29.66 | 34.3 ± 40.20 |
| Complement C4: Change at Week 48 | -0.4 ± 20.74 | 33.3 ± 18.90 | 16.0 ± 27.89 |
| Complement C4: Change at Week 72 | -43.0 ± 82.46 | 12.0 ± 17.35 | 49.7 ± 30.02 |
| Complement C4: Change at Early Termination | -22.0 ± 32.53 | -8.0 ± 38.57 | 125.0 |
| Complement C4: Change at PT FU Week 12 | -12.6 ± 32.00 | -4.2 ± 9.07 | -1.3 ± 44.52 |
| Complement C4: Change at PT FU Week 24 | -37.0 ± 64.97 | -18.2 ± 30.34 | 19.5 ± 18.30 |
Change from baseline in immune cell subsets included total T cells, helper T cells, cytotoxic T cells, total B cells (assay with \[AW\] CD45 or assay without \[AWO\] CD45), mature naïve B cells, memory B cells, plasma cells, plasma blasts, and natural killer (NK) cells and were reported. Analysis was performed by flow cytometry analysis.
| cells per microliter | Placebo | Atacicept 25 mg | Atacicept 75 mg |
|---|---|---|---|
| Cytotoxic T Cells: Change at Week 4 | — | -22.5 ± 215.67 | 46.7 ± 72.57 |
| Cytotoxic T Cells: Change at Week 12 | 713.0 | -114.0 | 75.0 ± 33.41 |
| Cytotoxic T Cells: Change at Week 24 | 101.5 ± 243.95 | -30.5 ± 125.16 | 37.0 ± 39.60 |
| Cytotoxic T Cells: Change at Week 48 | 9.0 ± 224.86 | — | 38.0 ± 42.43 |
| Cytotoxic T Cells: Change at Week 72 | -60.0 | — | -186.0 ± 289.91 |
| Cytotoxic T Cells: Change at Early Termination | 282.0 | — | 45.0 |
| Cytotoxic T Cells: Change at PT FU Week 24 | 132.0 | — | — |
| Helper T Cells: Change at Week 4 | — | 59.0 ± 240.42 | 114.7 ± 117.05 |
| Helper T Cells: Change at Week 12 | 124.0 | -51.0 | 221.3 ± 85.33 |
| Helper T Cells: Change at Week 24 | -79.0 ± 190.92 | 134.0 ± 124.45 | 85.0 ± 45.25 |
| Helper T Cells: Change at Week 48 | -129.5 ± 338.70 | — | 72.5 ± 86.97 |
| Helper T Cells: Change at Week 72 | -170.0 | — | -312.5 ± 427.80 |
| Helper T Cells: Change at Early Termination | 81.0 | — | 348.0 |
| Helper T Cells: Change at PT FU Week 24 | 90.0 | — | — |
| Mature naive B Cells: Change at Week 4 | — | -76.5 ± 12.02 | -17.0 ± 78.31 |
| Mature naive B Cells: Change at Week 12 | 137.0 | -106.0 | -14.7 ± 94.07 |
| Mature naive B Cells: Change at Week 24 | 1.0 ± 42.43 | -117.5 ± 51.62 | -87.5 ± 109.60 |
| Mature naive B Cells: Change at Week 48 | 21.5 ± 74.25 | — | -91.0 ± 107.48 |
| Mature naive B Cells: Change at Week 72 | -24.0 | — | -32.0 |
| Mature naive B Cells: Change at Early Termination | 36.0 | — | -1.0 |
| Mature naive B Cells: Change at PT FU Week 24 | 8.0 | — | — |
| Memory B Cells: Change at Week 4 | — | 8.0 | 14.5 ± 2.12 |
| Memory B Cells: Change at Week 12 | 5.0 | — | 34.0 ± 0.00 |
| Memory B Cells: Change at Week 24 | -1.5 ± 7.78 | 13.0 | 5.5 ± 21.92 |
| Memory B Cells: Change at Week 48 | -1.0 ± 4.24 | — | 5.0 ± 16.97 |
| Memory B Cells: Change at Week 72 | -6.0 | — | 8.0 |
| Memory B Cells: Change at Early Termination | -3.0 | — | — |
| Memory B Cells: Change at PT FU Week 24 | 6.0 | — | — |
| NK Cells: Change at Week 4 | — | 19.0 ± 227.69 | 88.3 ± 30.62 |
| NK Cells: Change at Week 12 | 43.0 | -105.0 | 74.0 ± 89.94 |
| NK Cells: Change at Week 24 | 44.5 ± 20.51 | -34.5 ± 112.43 | 37.5 ± 58.69 |
| NK Cells: Change at Week 48 | 20.5 ± 16.26 | — | 39.0 ± 48.08 |
| NK Cells: Change at Week 72 | 130.0 | — | 104.0 |
| NK Cells: Change at Early Termination | 54.0 | — | 12.0 |
| NK Cells:Change at PT FU Week 24 | 81.0 | — | — |
| Plasma Blasts: Change at Week 4 | — | 0.10 | -0.05 ± 0.071 |
| Plasma Blasts: Change at Week 12 | -0.10 | — | 0.55 ± 0.212 |
| Plasma Blasts: Change at Week 24 | 0.05 ± 0.071 | -0.30 | 0.10 ± 0.283 |
| Plasma Blasts: Change at Week 48 | 1.40 ± 1.414 | — | 0.15 ± 0.212 |
| Plasma Blasts: Change at Week 72 | -0.10 | — | 0.40 |
| Plasma Blasts: Change at Early Termination | 0.80 | — | — |
| Plasma Blasts: Change at PT FU Week 24 | 3.40 | — | — |
| Plasma Cells: Change at Week 4 | — | 0.10 | 0.00 ± 0.141 |
| Plasma Cells: Change at Week 12 | -0.10 | — | 0.15 ± 0.212 |
| Plasma Cells: Change at Week 24 | 0.05 ± 0.071 | -0.10 | 0.00 ± 0.000 |
| Plasma Cells: Change at Week 48 | 0.30 ± 0.283 | — | 0.00 ± 0.000 |
| Plasma Cells: Change at Week 72 | 0.00 | — | 0.20 |
| Plasma Cells: Change at Early Termination | 0.20 | — | — |
| Plasma Cells: Change at PT FU Week 24 | 0.10 | — | — |
| Total B cells (AW CD45): Change at Week 4 | — | -50.0 ± 36.77 | 37.3 ± 64.39 |
| Total B cells (AW CD45): Change at Week 12 | 154.0 | -105.0 | 108.7 ± 88.90 |
| Total B cells (AW CD45): Change at Week 24 | -0.5 ± 57.28 | -78.0 ± 131.52 | -32.5 ± 116.67 |
| Total B cells (AWh CD45): Change at Week 48 | 20.0 ± 91.92 | — | -27.5 ± 115.26 |
| Total B cells (AW CD45): Change at Week 72 | -31.0 | — | 2.0 |
| Total B cells (AW CD45): Change at Early Termination | 43.0 | — | 71.0 |
| Total B cells (AW CD45): Change at PT FU Week 24 | 27.0 | — | — |
| Total B cells (AWO CD45): Change at Week 4 | — | -33.0 ± 104.65 | 41.0 ± 40.60 |
| Total B cells (AWO CD45): Change at Week 12 | 16.0 | -137.0 | 52.0 ± 65.09 |
| Total B cells (AWO CD45): Change at Week 24 | -11.0 ± 53.74 | -96.5 ± 135.06 | -40.5 ± 88.39 |
| Total B cells (AWO CD45): Change at Week 48 | 9.0 ± 113.14 | — | -52.5 ± 81.32 |
| Total B cells (AWO CD45): Change at Week 72 | -38.0 | — | -78.0 |
| Total B cells (AWO CD45): Change at Week Early Termination | 23.0 | — | 48.0 |
| Total B cells (AWO CD45): Change at PT FU Week 24 | -36.0 | — | — |
| Total T Cells: Change at Week 4 | — | 40.0 ± 466.69 | 169.0 ± 189.71 |
| Total T Cells: Change at Week 12 | 861.0 | -165.0 | 314.7 ± 50.54 |
| Total T Cells: Change at Week 24 | 18.5 ± 419.31 | 111.0 ± 260.22 | 130.0 ± 2.83 |
| Total T Cells: Change at Week 48 | -116.5 ± 564.98 | — | 113.5 ± 140.71 |
| Total T Cells: Change at Week 72 | -227.0 | — | -529.5 ± 767.21 |
| Total T Cells: Change at Early Termination | 350.0 | — | 393.0 |
| Total T Cells: Change at PT FU Week 24 | 220.0 | — | — |
Urinary IgG, IgA and IgM levels to be measured by Immuno-Electrophoresis.
No measurements were reported for this outcome.
Percentage of participants with positive ADA were reported.
| percentage of participants | Placebo | Atacicept 25 mg | Atacicept 75 mg |
|---|---|---|---|
| Percentage of Participants With Positive Anti-Drug Antibody (ADA) | 0 | 0 | 0 |
Laboratory investigation included hematology, biochemistry, urinalysis and Urine sediment analysis. Clinical significance was to be decided by the investigator.
No measurements were reported for this outcome.
Vital signs included body temperature, systolic and diastolic blood pressure, pulse rate, weight and height. The systolic and diastolic blood pressure and pulse rate was measured after the participants have in a rested at least 3 minutes in seated position. Clinical significance was to be decided by the investigator.
No measurements were reported for this outcome.
12-lead ECG were recorded after the participants have rested for at least 15 minutes in supine position. Clinically significance was decided by the investigator. The number of participants with clinically significant abnormalities in 12-lead ECG were reported.
| percentage of participants | Placebo | Atacicept 25 mg | Atacicept 75 mg |
|---|---|---|---|
| Percentage of Participants With Clinical Significant Abnormalities in 12-Lead Electrocardiograms (ECGs) | 0 | 0 | 0 |
Collected over Baseline up to safety follow up period (96 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/5 (0%) | 1/5 (20%) | 5/5 (100%) |
| Atacicept 25 mg | 0/6 (0%) | 3/6 (50%) | 6/6 (100%) |
| Atacicept 75 mg | 0/5 (0%) | 0/5 (0%) | 3/5 (60%) |
| Event | Placebo | Atacicept 25 mg | Atacicept 75 mg |
|---|---|---|---|
| Ovarian adenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/5 | 0/6 | 0/5 |
| Acute kidney injuryRenal and urinary disorders | 0/5 | 1/6 | 0/5 |
| Urinary bladder haemorrhageRenal and urinary disorders | 0/5 | 1/6 | 0/5 |
| Gastroenteritis viralInfections and infestations | 0/5 | 1/6 | 0/5 |
| Cervical spinal stenosisMusculoskeletal and connective tissue disorders | 0/5 | 1/6 | 0/5 |
| Event | Placebo | Atacicept 25 mg | Atacicept 75 mg |
|---|---|---|---|
| Injection site erythemaGeneral disorders | 0/5 | 4/6 | 1/5 |
| Injection site bruisingGeneral disorders | 0/5 | 3/6 | 0/5 |
| Injection site pruritusGeneral disorders | 0/5 | 3/6 | 0/5 |
| Urinary tract infectionInfections and infestations | 0/5 | 3/6 | 0/5 |
| Injection site reactionGeneral disorders | 0/5 | 1/6 | 2/5 |
| DiarrhoeaGastrointestinal disorders | 2/5 | 0/6 | 0/5 |
| Gastroenteritis viralInfections and infestations | 0/5 | 2/6 | 0/5 |
| InfluenzaInfections and infestations | 0/5 | 2/6 | 0/5 |
| PruritusSkin and subcutaneous tissue disorders | 0/5 | 2/6 | 0/5 |
| Injection site inflammationGeneral disorders | 0/5 | 0/6 | 1/5 |
The modified intent-to-treat (mITT) population included all randomized participants who had received at least 1 dose of the Investigational Medicinal Product (IMP).
| Age, Continuous(years) | Placebo | Atacicept 25 mg | Atacicept 75 mg | Total |
|---|---|---|---|---|
| Mean | 46 ± 3.1 | 41 ± 16.9 | 43 ± 8.7 | 43 ± 11.1 |
| Sex: Female, Male(Participants) | Placebo | Atacicept 25 mg | Atacicept 75 mg | Total |
|---|---|---|---|---|
| Female | 1 | 5 | 2 | 8 |
| Male | 4 | 1 | 3 | 8 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Atacicept 25 mg | Atacicept 75 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 3 | 4 |
| Not Hispanic or Latino | 5 | 5 | 2 | 12 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | Atacicept 25 mg | Atacicept 75 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 1 | 1 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 4 | 5 | 2 | 11 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 2 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Per company policy, following approval of a new product or a new indication for an approved product in both the EU and the US, EMD Serono will share study protocols, anonymized patient level and study level data and redacted clinical study reports from clinical trials in patients with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website.
Data sharing details ↗ · www.emdgroup.com
Ran from Jan 2017 to primary completion in Feb 2020, 36 months.
Results were first posted in Feb 2021, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TACI receptor-IgG Fc fragment fusion protein
EMD Serono Research & Development Institute, Inc. →